Zacks Investment Research on MSN2d
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors
This was the stock's second consecutive day of losses.
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives Outperform Rating from Wedbush
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by ...
What is Lifesci Capital’s Forecast for CRBP Q1 Earnings?
Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...
Corbus Pharmaceuticals reports Q4 EPS (78c), consensus ($1.26)
During the fourth quarter and into 2025, we made significant progress across our pipeline. Both of our oncology programs have been advancing ...
William Blair Reaffirms Their Hold Rating on Terns Pharmaceuticals (TERN)
In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on Terns Pharmaceuticals (TERN – Research Report). The ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Yahoo Finance3d
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.9% over the past four weeks, the stock looks well positioned for a trend ...